Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 10/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | UBE2N | P61088 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916507 | 0.88 | POLB (0.45) | POLBMAPTSMN1; SMN2HPGDLMNA | |
| Acetic Acid SCHEMBL2066916 | 0.86 | POLB (0.52) | TDP1POLBMAPTSMN1; SMN2HPGD | |
| Acetic Acid SCHEMBL2066918 | 0.86 | POLB (0.52) | TDP1POLBMAPTSMN1; SMN2HPGD | |
| SCHEMBL5571385 | 0.86 | POLB (0.53) | TDP1POLBMAPTSMN1; SMN2HPGD | |
| SCHEMBL5571382 | 0.86 | POLB (0.53) | TDP1POLBMAPTSMN1; SMN2HPGD | |
| SCHEMBL916609 | 0.84 | MAPT (0.59) | TDP1POLBMAPTSMN1; SMN2HPGD | |
| SCHEMBL915608 | 0.81 | ALDH1A1 (0.61) | TDP1POLBMAPTSMN1; SMN2HPGD | |
| SCHEMBL917384 | 0.79 | ALDH1A1 (0.49) | TDP1POLBMAPTSMN1; SMN2HPGD | |
| SCHEMBL13673565 | 0.79 | MAPT (0.46) | TDP1POLBMAPTSMN1; SMN2HPGD | |
| Water SCHEMBL915672 | 0.78 | MAPT (0.45) | TDP1POLBMAPTSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227927-B2 | Method of treating inflammation | ANAMAR AB (SE) | 2016-01-05 | — | — | US | disclosed |
| US-20130295009-A1 | METHOD OF TREATING INFLAMMATION | HPF IP HOLDING S.A. (LU) | 2013-11-07 | — | — | US | disclosed |
| US-20120178820-A1 | METHOD FOR TREATING ARTHRITIS | ANAMAR AB (SE) | 2012-07-12 | — | — | US | disclosed |
| US-8148429-B2 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | ANAMAR AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-20070231267-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | ACURE PHARMA AB (SE) | 2007-10-04 | — | — | US | disclosed |
| US-20070088085-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | MELACURE THERAPEUTICS AB (SE) | 2007-04-19 | — | — | US | disclosed |
| US-20040024060-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | ACURE PHARMA AB (SE) | 2004-02-05 | — | — | US | disclosed |
| WO-2001025192-A1 | GUANIDINE DERIVATIVES AND THEIR USE IN THE PRODUCTION OF A MEDICAMENT FOR BLOCKING XANTHINE OXIDASE/DEHYDROGENASE | MELACURE THERAPEUTICS AB (SE) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231267-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | MC1R, MC5R, MCHR1 | TDP1 3518/4885POLB 3668/4885MAPT 4502/4885 |
| US-20040024060-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | MC1R, MC5R, MCHR1 | TDP1 3469/4885POLB 3659/4885MAPT 4496/4885 |
| US-20070088085-A1 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | MC1R, MC5R, MCHR1 | TDP1 3518/4885POLB 3668/4885MAPT 4502/4885 |
| US-20130295009-A1 | METHOD OF TREATING INFLAMMATION | MC2R, MC5R, MC1R | TDP1 4360/4885POLB 3116/4885MAPT 3465/4885 |
| US-20120178820-A1 | METHOD FOR TREATING ARTHRITIS | MC5R, MC1R, MC2R | TDP1 3706/4885POLB 3257/4885MAPT 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.